Cheke RA. Factors affecting onchocerciasis transmission: lessons for infection control. Expert Rev Anti-Infect Ther. 2017;4:377–86.
Article
Google Scholar
Weldegebreal F, Medhin G, Weldegebreal Z, Legesse M. Assessement of community’s knowledge, attitude and pratice about onchocerciasis and community directed treatment with Ivermectin in Quara District, north westem Ethiopia. Parasit Vectors. 2014;7:90–8.
Article
Google Scholar
Murdoch ME, Asuzu MC, Hagan M, Makunde WH, Ngoumou P, Ogbuagu KF, Okello D, Ozoh G, Remme J. Onchocerciasis: the clinical and epidemiologie burden of skin disease in Africa. Ann Top Med Parasitol. 2002;96:283–96.
Article
CAS
Google Scholar
Murdoch ME, Murdoch IE, Evans J, Yahaya H, Njepuome N, Cousens S, Jones BR, Abiose A. Pre-control relationship of onchocercal skin disease with onchocercal infection in Guinea savanna. Northern Nigeria PLoS Negl Trop Dis. 2017;11:1–19.
Google Scholar
Benton B. Economic impact of onchocerciasis control through the African program for onchocerciasis control: an overview. Ann Trop Med Parasitol. 1998;92:S33–9.
Article
Google Scholar
Tchounkeu YF, Onyeneho NG, Wanji S, Kabali AT, Manianga C, Amazingo UV, Amuyunzu-Nyamongo M. Changes in stigma and discrimination of onchocerciasis in Africa. Trans R Soc Trop Med Hyg. 2012;106:340–7.
Article
Google Scholar
Makenga Bof J-C, Mpunga D, Soa EN, Ntumba F, Bakajika D, Murdoch ME, Coppieters Y. Onchocerciasis in the Democratic Republic of Congo: Survey of knowledge, attitude and perception in Bandundu province. Journal of Infection and Public Health. 2017;10:600-7.
Article
Google Scholar
World Health Organisation (WHO) (2017) Unprecedented progress against neglected tropical diseases. WHO reports 2017; available at: http://www.who.int/mediacentre/news/releases/2017/ntd-report/fr/ [consulted on Dec 22, 2017].
Basáñez MG, Churcher TS PSD, Breitling LP, Little MP, Boussinesq M. River blindness: a success story under threat? PLoS Med. 2006;3:1454–60.
Article
Google Scholar
Sauerbrey M. The onchocerciasis elimination program for the Americas (OEPA). Ann Trop Med Parasitol. 2008;102:25–9.
Article
Google Scholar
Abdul-Ghani R, Mahdy MA, Beier JC. Onchocerciasis in Yemen: time to take action against a neglected tropical parasitic disease. Acta Trop. 2016;162:133–41.
Article
Google Scholar
Boatin B. The onchocerciasis control program in West Africa (OCP). Ann Trop Med Parasitol. 2008;1:13–7.
Article
Google Scholar
World Health Organisation (WHO) (2018) Disease Watch Focus: Onchocerciasis. WHO 2018. Available at: http://www.who.int/tdr/publications/disease_watch/oncho/en/ [consulted on Jul 15, 2018].
Makenga Bof J-C, Maketa V, Bakajika DK, Ntumba F, Mpunga D, Murdoch ME, Hopkins A, Noma MM, Zouré H, Tekle AH, Katabarwa MN, Lutumba P. Onchocerciasis control in the Democratic Republic of Congo (DRC): challenges in a post-war environment. Trop Med Int Health. 2015;20:48–62.
Article
Google Scholar
Ministère de la Santé Publique, Secrétariat Général, RDC (2016). Programme National de Lutte contre les Maladies Tropicales Négligées. Plan Stratégique de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive 2016–2020. Kinshasa, RDC p 1–179.
Dimomfu BL, Lubeji DK, Noma M, Beketeli A, Boussines M. Sociological study in three foci of Central Africa before the implementation of treatments with ivermectin (Mectizan). APOC Trans R Soc Trop Med Hyg. 2007;101:674–9.
Article
Google Scholar
Samuel A, Belay T, Yehalaw D, Taha M, Zemene E, Zeynudin A. Impact of six years community directed treatment with Ivermectin in the control of onchocerciasis. Western Ethiopia PLoS One. 2016;11:1–9.
Google Scholar
World Health Organisation (WHO) (2015) Weekly epidemiological record. N°49. 90:661–680.
World Health Organisation (WHO) (2018) African Program for Onchocerciasis Control (APOC). Community-directed treatment with ivermectin (CDTI). Available at: http://www.who.int/apoc/cdti/en/ [consulted on March 24, 2018].
Mr Ahamadou Houna (2014) [Study of adverse effects of medicine used during the campaign against neglected tropical diseases] [in French]. Faculté de médecine et d’odontostomatologie, Université des sciences, des techniques et des technologiques, Bamako, République du Mali. PhD, academic year 2013–2014.
World Health Organisation (WHO) (2018) African Program for Onchocerciasis Control (APOC). Ivermectin. Available at: http://www.who.int/apoc/cdti/ivermectin/en/ [consulted on March 24, 2018].
Ducorps M, Gardon-wendel N, Ranque S, Ndong W, Boussinesq M, Gardon J, Schneider D, Chippaux J-P. [Adverse reactions following ivermectin treatment in patients with high Loa loa parasitaemia] [in French]. Bull Soc Path. 1995;88:105–12.
CAS
Google Scholar
Carme B, Ebiliki B, Mbitsi A, Eopin N. [Clinical trial of ivermectin for the treatment of low to moderate Loa loa microfilaraemia] [in French]. Ann. Soc. belge Méd Trop. 1991;71:47–50.
CAS
Google Scholar
Chippaux J-P, Ernould J-C, Gardon J, Gardon-wendel N, Chandre F, Barberi N. Ivermectin treatment of loiasis. Trans Roy Soc Trop Med Hyg. 1992;86:280–9.
Google Scholar
Hovette P, Debonne JM, Touze JE, Gaxotte P, Imbert P, Fourcade I, Laroche R. Efficacy of ivermectin treatment of Loa loa filariasis patients without microfilaraemias. Ann Trop Med Parasitol. 1994;88:93–4.
Article
CAS
Google Scholar
Martin-Prevel Y, Cosnefroy JY, Tshipamba P, Ngari P, Chodakewitz JA, Pinder M. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg. 1993;48:186–92.
Article
CAS
Google Scholar
Paris I, Datry A, Durepaire R, Felix H, Gaxotte P, Danis M & Gentilini M (1991)– [Interest of ivermectin in the initial treatment of loiasis] [in French]. Presse Méd. 20: 1383–1393.
Richard-Lenoble D, Kombila M, Rupp EL, Pappayliou ES, Gaxotte P, Nguiri C, Aziz M. Ivermectin in loiasis and concomitant O. vulvulus and M. perstans infections. Am J Trop Med Hyg. 1988;39:480–3.
Article
CAS
Google Scholar
Anonyme. Encephalitis following treatment of loiasis. WHO Drug information. 1991;5:113–4.
Google Scholar
Anonyme. Ivermectin: a possible neurotoxicity. WHO Drug information. 1991;5:127–8.
Google Scholar
Chippaux J P, Ducorps M, Ranque S, Gardon N, Boussinesq M, Ndong W, Fobi G, Schneider D, Cot S & Garcia A (1994)- Adverse reactions following ivermectin treatment in patients with high Loa loa parasitaemia. 43rd annual meeting, am. Soc. trop. Med. Hyg., Cincinnati, USA, nov. 13-17.
Chippaux JP, Garcia A, Ranque S, Schneider D, Boussinesq M, Cot S, Le Hesran JY, Cot M. Adverse reactions following ivermectin treatment in hyperendemic loiasis area, joint annual meeting of the am. Soc. trop. Med. Hyg. And the am. Soc. Parasitol., 31 oct.4 nov. 1993, Atlanta, USA, abstract in am. J Trop Med Hyg. 1993;49:1–161.
Article
Google Scholar
Ernould J C (1993) [Feasibility study of a collective treatment against Loa loa with ivermectin in two villages of South-Cameroon] [in French]. PhD, Faculty of Medecine, 1993, Université de Nantes (France).
National Program for Onchocerciasis Control (NPOC). [Annual technical report of the National Coordination Group for onchocerciasis (NCGO)] [in French] Kasai occidental project. Kinshasa, DRC. 2002;2002:1–50.
Google Scholar
National Program for Onchocerciasis Control (NPOC). [Annual technical report of the National Coordination Group for onchocerciasis (NCGO)] [in French]. Bas Uelé project, Kinshasa, DRC. 2009;2009:1–50.
Google Scholar
Kamgno J, Pion SD, Tejiokem MC, Twum-Danso NA, Thylefors B, Boussinesq M. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg). Trans R Soc Trop Med Hyg. 2007;101:777–85.
Article
CAS
Google Scholar
Makenga Bof JC, Ntumba F, Mpunga D, Paul Mansiangi P, Ilunga-Ilunga F, Coppieters Y. Evolution of areas and factors associated with no community-directed treatment with Ivermectin, Democratic Republic of Congo. J Infect Dev Ctries. 2018;12:771–9.
Article
Google Scholar
DRC Ministry of Public Health: National Program for Onchocerciasis Control (NPOC) (2017) “SAE data”, Kinshasa; DRC.
DRC Ministry of Public Health: National Program for Onchocerciasis Control (NPOC) (2015): “ Rapid Assessment Procedure for Loiasis ” (RAPLOA) and the “ Rapid Epidemiological Assessment ” for Onchocerciasis (REA), Kinshasa; DRC.
Chippaux JP, Bouchité B, Boussinesq M, Ranque S, Baldet T, Demanou M. Impact of repeated large scale ivermectin treatments on the transmission of Loa loa. Trans R Soc Trop Med Hyg. 1998;92:454–8.
Article
CAS
Google Scholar
Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg. 2008;78:546–51.
Article
CAS
Google Scholar
Wanji S, Eyong EJ, Tendongfor N, Ngwa CJ, Esuka EN, Kengne-Ouafo AJ, Datchoua-Poutcheu FR, Enyong P, Agnew D, Eversole RR, Hopkins A, Mackenzie CD. Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment. PLoS Negl Trop Dis. 2017;11:1–25.
Article
Google Scholar
Nzolo D, Anto F, Hailemariam S, Bakajika D, Muteba D, Makenga JC, Mesia G, Nsibu C, Mampunza S, Tona G. Central and peripheral nervous system disorders following Ivermectin mass administration: a descriptive study based on the Democratic Republic of Congo pharmacovigilance system. Drugs Real World Outcomes. 2017;4:151–8.
Article
Google Scholar
Fobi G, Gardon J, Santiago M, Ngangue D, Gardon-Wendel N, Boussinesq M. Ocular findings after ivermectin treatment of patients with high Loa loa microfilaraemia. Ophthalmic Epidemiol. 2000;7:27–39.
Article
CAS
Google Scholar
Otubanjo OA, Adeoye GO, Ibidapo CA, Akinsanya B, Okeke P, Atalabi T, Adejai ET, Braide E. Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo state. Nigeria. Rev Biol Trop. 2008;56:1635–43.
CAS
PubMed
Google Scholar
Homeida MM, Malcolm SB, ElTayeb AZ, Eversole RR, Elassad AS, Geary TG, Ali MM, Mackenzie CD. The lack of influence of food and local alcoholic brew on the blood level of Mectizan® (ivermectin). Acta Trop. 2013;127:97–100.
Article
CAS
Google Scholar
Sparsa A, Bonnetblanc J-M, Peyrot I, Loustaud-Ratti V, Vidal E, Bédane C. Systemic adverse reactions with ivermectin treatment of scabies. Ann Dermatol Venereol. 2006;133:10784–7.
Google Scholar
Grotenhermen F (2004) [medicinal use of cannabis. A practical guide of cannabis and THC therapeutic uses] [in German] 2004, AT Verlag, Baden und München (Germany),1 - 192.
Oyibo WA, Fagbenro-Beyioku AF. Adverse reactions following annual ivermectin treatment of onchocerciasis in Nigeria. Int J Infect Dis. 2003;7:156–9.
Article
Google Scholar
Kamgno J, Pion SD, Chesnais CB, Bakalar MH, D'Ambrosio MV, Mackenzie CD, Nana-Djeunga HC, Gounoue-Kamkumo R, Njitchouang GR, Nwane P, Tchatchueng-Mbouga JB, Wanji S, Stolk WA, Fletcher DA, Klion AD, Nutman TB, Boussinesq M. A test-and-not-treat strategy for onchocerciasis in Loa loa-endemic areas. N Engl J Med. 2017;377:2044–52.
Article
Google Scholar
World Health Organisation (WHO) (1991) Settling problems related to alcohol (In French). WHO, Regional Publications, European Series, No. 32 ISBN 92 890 2123 3 ISSN 0250–8575.
Grotenhermen F, Müller-Vahl K. The therapeutic potential of Cannabis and cannabinoids. Dtsch Arztebl Int. 2012;109:495–501.
PubMed
PubMed Central
Google Scholar